Cargando…

The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation

Ciclesonide is an FDA-approved glucocorticoid (GC) used to treat asthma and allergic rhinitis. However, its effects on cancer and cancer stem cells (CSCs) are unknown. Our study focuses on investigating the inhibitory effect of ciclesonide on lung cancer and CSCs and its underlying mechanism. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Hack Sun, Kim, Su-Lim, Kim, Ji-Hyang, Lee, Dong-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038186/ https://www.ncbi.nlm.nih.gov/pubmed/32033067 http://dx.doi.org/10.3390/ijms21031014

Ejemplares similares

The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway
por: Kim, Su-Lim, et al.
Publicado: (2020)

Ciclesonide for the treatment of asthma
por: Dahl, Ronald
Publicado: (2006)

Profile of ciclesonide for the maintenance treatment of asthma
por: Singas, Effie, et al.
Publicado: (2011)

Efficacy of ciclesonide in the treatment of patients with asthma exacerbation
por: Zietkowski, Ziemowit, et al.
Publicado: (2019)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Ciclesonide in persistent asthma: the evidence of its therapeutic value
por: Kenreigh, Charlotte A., et al.
Publicado: (2006)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma
por: Schaffner, Timothy J, et al.
Publicado: (2009)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

112 Comparison of the Use Ciclesonide Versus Fluticasone for the Treatment of Asthma in Children
por: Oropeza, Said Arablin, et al.
Publicado: (2012)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
por: Ramakrishnan, Gayatri, et al.
Publicado: (2017)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus
por: Yeo, Won-Sik, et al.
Publicado: (2018)

Efficacy of Low-Dose Ciclesonide and Fluticasone Propionate for Mild to Moderate Persistent Asthma
por: Jamaati, Hamidreza, et al.
Publicado: (2015)

A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation
por: Salvi, Sundeep S, et al.
Publicado: (2016)

A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation
por: Barthwal, Madhu Sudan, et al.
Publicado: (2017)

Intranasal ciclesonide for allergic rhinitis
por: Williams, Ben, et al.
Publicado: (2008)

Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa
por: Sato, Hideyuki, et al.
Publicado: (2007)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

Disruption of the NF-κB/IL-8 Signaling Axis by Sulconazole Inhibits Human Breast Cancer Stem Cell Formation
por: Choi, Hack Sun, et al.
Publicado: (2019)

Synthesis and clinical application of new drugs approved by FDA in 2022
por: Zhang, Jing-Yi, et al.
Publicado: (2023)

The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation
por: Kim, Ji-Hyang, et al.
Publicado: (2019)

Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children
por: Chera, Alexandra, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
por: Hou, Zhi-Jie, et al.
Publicado: (2015)

Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
por: Postma, Dirkje S., et al.
Publicado: (2017)

A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room
por: Martins, Demétrius Tierno, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_21nk56lin0gug5hr9bmo1k5i1u